319 related articles for article (PubMed ID: 31994958)
1. Selective inhibitors for JNK signalling: a potential targeted therapy in cancer.
Wu Q; Wu W; Jacevic V; Franca TCC; Wang X; Kuca K
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):574-583. PubMed ID: 31994958
[TBL] [Abstract][Full Text] [Related]
2. Targeting JNK and its role in tumor development and chemoresistance.
Wu Q; Kuca K; Wu W
Future Med Chem; 2020 Jun; 12(12):1103-1105. PubMed ID: 32372662
[No Abstract] [Full Text] [Related]
3. Conflicting evidence for the role of JNK as a target in breast cancer cell proliferation: Comparisons between pharmacological inhibition and selective shRNA knockdown approaches.
Wood RA; Barbour MJ; Gould GW; Cunningham MR; Plevin RJ
Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417765
[TBL] [Abstract][Full Text] [Related]
4. JNK signaling as a target for anticancer therapy.
Abdelrahman KS; Hassan HA; Abdel-Aziz SA; Marzouk AA; Narumi A; Konno H; Abdel-Aziz M
Pharmacol Rep; 2021 Apr; 73(2):405-434. PubMed ID: 33710509
[TBL] [Abstract][Full Text] [Related]
5. Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents.
Messoussi A; Feneyrolles C; Bros A; Deroide A; Daydé-Cazals B; Chevé G; Van Hijfte N; Fauvel B; Bougrin K; Yasri A
Chem Biol; 2014 Nov; 21(11):1433-43. PubMed ID: 25442375
[TBL] [Abstract][Full Text] [Related]
6. Galloyl benzamide-based compounds modulating tumour necrosis factor α-stimulated c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signalling pathways.
Leo V; Stefanachi A; Nacci C; Leonetti F; de Candia M; Carotti A; Altomare CD; Montagnani M; Cellamare S
J Pharm Pharmacol; 2015 Oct; 67(10):1380-92. PubMed ID: 26078032
[TBL] [Abstract][Full Text] [Related]
7. JNK signalling in cancer: in need of new, smarter therapeutic targets.
Bubici C; Papa S
Br J Pharmacol; 2014 Jan; 171(1):24-37. PubMed ID: 24117156
[TBL] [Abstract][Full Text] [Related]
8. Juglanin induces apoptosis and autophagy in human breast cancer progression via ROS/JNK promotion.
Sun ZL; Dong JL; Wu J
Biomed Pharmacother; 2017 Jan; 85():303-312. PubMed ID: 27899257
[TBL] [Abstract][Full Text] [Related]
9. c-Jun N-terminal kinase inhibitor SP600125 enhances barrier function and elongation of human pancreatic cancer cell line HPAC in a Ca-switch model.
Konno T; Ninomiya T; Kohno T; Kikuchi S; Sawada N; Kojima T
Histochem Cell Biol; 2015 May; 143(5):471-9. PubMed ID: 25511417
[TBL] [Abstract][Full Text] [Related]
10. Conditional expression of MAP kinase phosphatase-2 protects against genotoxic stress-induced apoptosis by binding and selective dephosphorylation of nuclear activated c-jun N-terminal kinase.
Cadalbert L; Sloss CM; Cameron P; Plevin R
Cell Signal; 2005 Oct; 17(10):1254-64. PubMed ID: 16038800
[TBL] [Abstract][Full Text] [Related]
11. JNK and ERK mitogen-activated protein kinases mediate THDA-induced apoptosis in K562 cells.
Yang SH; Wu ZZ; Chien CM; Lo YH; Wu MJ; Chang LS; Lin SR
Cell Biol Toxicol; 2008 Aug; 24(4):291-302. PubMed ID: 17934787
[TBL] [Abstract][Full Text] [Related]
12. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway.
Li Y; Mao Y; Brandt-Rauf PW; Williams AC; Fine RL
Mol Cancer Ther; 2005 Jun; 4(6):901-9. PubMed ID: 15956247
[TBL] [Abstract][Full Text] [Related]
13. Suppression of reactive oxygen species-mediated ERK and JNK activation sensitizes dihydromyricetin-induced mitochondrial apoptosis in human non-small cell lung cancer.
Kao SJ; Lee WJ; Chang JH; Chow JM; Chung CL; Hung WY; Chien MH
Environ Toxicol; 2017 Apr; 32(4):1426-1438. PubMed ID: 27539140
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of protein kinase C α/βII and activation of c-Jun NH2-terminal kinase mediate glycyrrhetinic acid induced apoptosis in non-small cell lung cancer NCI-H460 cells.
Song J; Ko HS; Sohn EJ; Kim B; Kim JH; Kim HJ; Kim C; Kim JE; Kim SH
Bioorg Med Chem Lett; 2014 Feb; 24(4):1188-91. PubMed ID: 24461294
[TBL] [Abstract][Full Text] [Related]
15. Trazodone treatment protects neuronal-like cells from inflammatory insult by inhibiting NF-κB, p38 and JNK.
Daniele S; Da Pozzo E; Zappelli E; Martini C
Cell Signal; 2015 Aug; 27(8):1609-29. PubMed ID: 25911310
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of c-Jun N-terminal kinase sensitizes tumor cells to flavonoid-induced apoptosis through down-regulation of JunD.
Kook SH; Son YO; Jang YS; Lee KY; Lee SA; Kim BS; Lee HJ; Lee JC
Toxicol Appl Pharmacol; 2008 Mar; 227(3):468-76. PubMed ID: 18078968
[TBL] [Abstract][Full Text] [Related]
17. c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).
Gehringer M; Muth F; Koch P; Laufer SA
Expert Opin Ther Pat; 2015; 25(8):849-72. PubMed ID: 25991433
[TBL] [Abstract][Full Text] [Related]
18. Agents targeting c-Jun N-terminal kinase pathway as potential neuroprotectants.
Zhang GY; Zhang QG
Expert Opin Investig Drugs; 2005 Nov; 14(11):1373-83. PubMed ID: 16255677
[TBL] [Abstract][Full Text] [Related]
19. c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells.
Khatlani TS; Wislez M; Sun M; Srinivas H; Iwanaga K; Ma L; Hanna AE; Liu D; Girard L; Kim YH; Pollack JR; Minna JD; Wistuba II; Kurie JM
Oncogene; 2007 Apr; 26(18):2658-66. PubMed ID: 17057737
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of c-Jun N-terminal kinases: JuNK no more?
Bogoyevitch MA; Arthur PG
Biochim Biophys Acta; 2008 Jan; 1784(1):76-93. PubMed ID: 17964301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
